News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 688 results
October 2019
September 2019
-
Story Discovery
Word on the Street: What is cell and gene therapy?We leave the lab to find out what people know about cell and gene therapy.
-
StatementForm 483 posting by US Food and Drug Administration (FDA) – Novartis statement
-
Media ReleaseAveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1BASEL, Switzerland, Sept. 19, 2019 /PRNewswire/ -- New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate…
-
Media ReleaseAveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
-
Media ReleaseEntresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings- Results from PROVE-HF trial show significant improvements in measures of cardiac structure and function at six months and one year in heart failure with reduced ejection fraction (HFrEF) patients;(…
-
Media ReleaseEntresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings
July 2019
-
Media ReleaseNovartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home- My Home in Sight, developed in partnership with six leading patient advocacy organizations, provides five key principles of adapting spaces in the home to support those impacted by wet AMD and…
-
Media ReleaseNovartis Teams Up With Celebrity Interior Designer Nate Berkus To Launch My Home In Sight, A Program Empowering People With Wet AMD To Live More Independently At Home
-
Media ReleaseFDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)- FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from…
-
Media ReleaseFDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)
-
Media ReleaseNovartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions- BRAF mutation status is an important factor when choosing a first-line therapy for patients with stage III and stage IV melanoma- The Know Now Testing Program covers cost of this genetic mutation…
Pagination
- ‹ Previous page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- …
- 58
- › Next page